XBP1 and neoplasm: The treatment with each checkpoint inhibitor also increased anti-tumor activities of XBP1/CD138/CS1-CTL against MM cells, evidenced by increased CD107a degranulation and IFN-γ production, with the highest anti-tumor activities induced by anti-LAG3 treatment (Fig. 6C).